•
AD
ADAG
Adagene Inc. American Depositary Shares
polygon--
Price Chart
Market Cap
88.14M
Volume
34.73K
52W High
$3.16
52W Low
$1.30
Open
$1.93
Prev Close
$1.87
Day Range
1.69 - 1.93
About Adagene Inc. American Depositary Shares
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
Latest News
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
GlobeNewswire Inc.•Nov 13
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
GlobeNewswire Inc.•Oct 31
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
GlobeNewswire Inc.•Sep 5
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
GlobeNewswire Inc.•Jul 15
Adagene announces up to $25 million strategic investment from Sanofi
GlobeNewswire Inc.•Jul 1
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
GlobeNewswire Inc.•Mar 13
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
GlobeNewswire Inc.•Nov 7
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
GlobeNewswire Inc.•Oct 9